Nucs AI

Nucs AI is a private healthcare AI company developing imaging-based software for prostate cancer detection, staging, treatment selection, and response monitoring. Its products are built around PSMA-PET/CT analysis and predictive biomarkers intended to support theranostics and precision oncology workflows. The company markets a platform that includes DeepPSMA, SelectPSMA, and TrackPSMA, spanning lesion detection, patient selection for PSMA-targeted radiopharmaceuticals, and longitudinal treatment-response assessment. Nucs AI positions itself at the intersection of radiology, nuclear medicine, and oncology, with collaborations aimed at expanding predictive imaging biomarkers for next-generation radioconjugates. The business appears to operate as an active venture-backed medtech/healthtech company rather than a drug developer.